These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9266131)

  • 1. The design of clinical trials aimed at assessing the DC-ART properties of new molecules in rheumatoid arthritis.
    Ortiz Z; Tugwell P; Yocum D
    Clin Exp Rheumatol; 1997; 15 Suppl 17():S39-44. PubMed ID: 9266131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endpoints in rheumatoid arthritis.
    Tugwell P; Boers M; Baker P; Wells G; Snider J
    J Rheumatol Suppl; 1994 Oct; 42():2-8. PubMed ID: 7823314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?
    Boers M
    Arthritis Rheum; 2003 Jun; 48(6):1481-3. PubMed ID: 12794813
    [No Abstract]   [Full Text] [Related]  

  • 4. Other special considerations in assessing DC-ART: The need for patient stratification.
    Edmonds J; Bosi Ferraz M
    J Rheumatol Suppl; 1994 Sep; 41():50-1. PubMed ID: 7799385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical considerations concerning clinical studies designed to assess DC-ARTs.
    Della Casa-Alberighi O; Ferrara R; Marubini E
    Clin Exp Rheumatol; 1997; 15 Suppl 17():S45-52. PubMed ID: 9266132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues.
    O'Dell JR
    Arthritis Rheum; 2007 Dec; 56(12):3884-6. PubMed ID: 18050217
    [No Abstract]   [Full Text] [Related]  

  • 7. DC-ART: the concept.
    Edmonds J
    J Rheumatol Suppl; 1994 Sep; 41():3-5; discussion 5-7. PubMed ID: 7799382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.
    Boers M; Tugwell P; Felson DT; van Riel PL; Kirwan JR; Edmonds JP; Smolen JS; Khaltaev N; Muirden KD
    J Rheumatol Suppl; 1994 Sep; 41():86-9. PubMed ID: 7799394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
    Felson DT; Smolen JS; Wells G; Zhang B; van Tuyl LH; Funovits J; Aletaha D; Allaart CF; Bathon J; Bombardieri S; Brooks P; Brown A; Matucci-Cerinic M; Choi H; Combe B; de Wit M; Dougados M; Emery P; Furst D; Gomez-Reino J; Hawker G; Keystone E; Khanna D; Kirwan J; Kvien TK; Landewé R; Listing J; Michaud K; Martin-Mola E; Montie P; Pincus T; Richards P; Siegel JN; Simon LS; Sokka T; Strand V; Tugwell P; Tyndall A; van der Heijde D; Verstappen S; White B; Wolfe F; Zink A; Boers M
    Ann Rheum Dis; 2011 Mar; 70(3):404-13. PubMed ID: 21292833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study.
    Christensen AW; Tarp S; Furst DE; Døssing A; Amris K; Bliddal H; Taylor PC; Christensen R
    PLoS One; 2015; 10(9):e0136982. PubMed ID: 26360583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial design for evaluating combination therapies.
    Paulus HE
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():92-5. PubMed ID: 8535656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement criteria--clinical and statistical significance: comment on the article by Pincus and Stein.
    van Gestel AM; van Riel PL
    Arthritis Rheum; 2000 Jul; 43(7):1658-60. PubMed ID: 10902775
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy assessment in trials of combination therapy for rheumatoid arthritis.
    Johnson K
    J Rheumatol Suppl; 1996 Mar; 44():107-9. PubMed ID: 8833066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
    Massarotti EM
    Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies: summary clinical trials working group.
    Weinblatt ME; van Riel PL
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii89. PubMed ID: 17038481
    [No Abstract]   [Full Text] [Related]  

  • 16. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness.
    Wolfe F; Michaud K
    Rheumatology (Oxford); 2005 Dec; 44 Suppl 4():iv18-iv22. PubMed ID: 16306476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis market.
    Mount C; Featherstone J
    Nat Rev Drug Discov; 2005 Jan; 4(1):11-2. PubMed ID: 15690597
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials.
    Kirkham J; Christensen R; Boers M
    Ann Rheum Dis; 2020 Feb; 79(2):301-302. PubMed ID: 31744828
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic strategies for rheumatoid arthritis.
    Smolen JS; Steiner G
    Nat Rev Drug Discov; 2003 Jun; 2(6):473-88. PubMed ID: 12776222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials: how to cope with medical needs, ethics and timelines.
    Rubbert-Roth A; Burmester GR
    Ann Rheum Dis; 2010 Jan; 69(1):1-3. PubMed ID: 20007619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.